• Member Login
  • Become a Member
  • Database Search
IATI - Israel Advanced Technology Industries
IATI - Israel Advanced Technology Industries
IATI News & Events Events Calendar Symposium : Cell Therapy – an Evolving Industry

Symposium : Cell Therapy – an Evolving Industry

Nov. 4, 2013



1+1 or 20% discount for IATI  members

Dear IATI Member,

Mr. Lee Buckler, managing director of Cell Therapy Group and Dr. Elmar Burchardt, VP regenerative medicine at Pfizer Inc. will discuss the current situation of the advanced therapy at the upcoming symposium "Cell Therapy – an Evolving Industry".

This event brings together international cell therapy leaders, executives, investors, R&D professionals and top scientists to explore scientific, medical and business aspects, interactions and collaborations.

I'm pleased to invite you to join this symposium that will take place on November 4, 2013 at Dan Hotel, Tel Aviv.

Please find more details below.

Don't hesitate to contact me for further information.

Best wishes,

Shifra Hoch
Scientific Manager
Bioforum Ltd.
Tel: +972-8-9313070, Ext. 3555
Cell: +972-50-8658874

If you can’t see this newsletter properly please click here


Invite you to the Symposium

November 4, 2013
Dan Hotel, Tel Aviv


Registration form
Hebrew     English




Opening Remarks



Cell Therapy: Will this  Academic Orphan Finally find a Loving Pharma Home?

Open discussion

Elmar Burchardt
Vice President, Regenerative Medicine, Pfizer Inc.



Coffee Break


Global Cell Therapy Industry Metrics, Trends, Analysis

Lee Buckler
Managing Director, Cell Therapy Group
Director,  Hemostemix


Taming of the Cell
How to Develop a Cell Therapy

Valentin Fulga
Founder and President Hemostemix


Lunch & Networking


Cell Therapy Trials
How CROs can Impact Trial Outcome

Surinder Kher
CEO Asia at Ecron Acunova


Cellular Product Analytics

Ina Sarel
Vice President of Research and Development, Hemostemix


Cell Therapy Business Models

Lee Buckler
Managing Director, Cell Therapy Group
Director,  Hemostemix


Coffee Break


Panel discussion
The Keys to the Future of Cell Therapy
as a Successful industry and Pillar of Healthcare

Lee Buckler, Elmar Burchardt, Valentin Fulga,
Avi Treves, Deputy Director, Sheba Cancer Research Center



Lee Buckler

buckler300-366 sm.jpgLee Buckler Lee is the founder and managing director of Cell Therapy Group – a business development consultancy focused on the cell therapy and regenerative medicine industry. He also recently joined the Board of Directors of Canadian-Israeli cell therapy company Hemostemix.

Since early 2000, Lee has been an executive in cell therapy regenerative medicine industry. He is also a frequent speaker, author, analyst, and commentator on the cell therapy sector at industry conferences, in trade publications, and on social media including his blog as well as on Twitter and LinkedIn.

Lee founded Cell Therapy News, launched and continues to manage the LinkedIn Cell Therapy Industry Group, and created Cell Therapy Blog where he continues to blog. Lee serves on the editorial board for both BioProcess International and Regenerative Medicine journals. Lee founded and served as Chair of ISCT's Cell Therapy Commercialization Committee (2006-9), serves now as the co-chair of the Alliance for Regenerative Medicine’s Communications and Education Committee and has served as an advisor to dozens of groups and projects in the regenerative medicine space outside of doing so in a consulting capacity.

Recent publications include co-authoring two book chapters, numerous articles in trade publications including Genetic Engineering News, and ARM’s 2013 Regenerative Medicine Annual Report as its Assistant Managing Editor.

Elmar Burchardt

burchardt.jpgElmar R. Burchardt, M.D., Ph.D.is Vice President, Regenerative Medicine, at Pfizer Inc. in Cambridge, Massachusetts. Pfizer is currently the only large pharmaceutical company clnically developing cell therapies in international multicenter trials.

Elmar has over 20 years of experience in the areas of cell therapy, hematology, inflammation and cardiovascular diseases. Before his appointment at Pfizer, he worked as Vice President of Medical Affairs for Aastrom Biosciences Inc. in Ann Arbor, Michigan. He initiated and led Aastrom’s US-based clinical cell therapy programs in cardiovascular diseases such as Critical Limb Ischemia (CLI) and Dilative Cardiomyopathy (DCM). Prior to that he worked for Miltenyi Biotec GmbH in Germany as their Medical Director, with global responsibilities including the development and market introduction strategy of 10 new clinical cell therapy products.

Prior to that time, Elmar worked at the Pharmaceutical Research Center of Bayer AG in Germany. Elmar studied medicine and biochemistry in Hannover, at Yale University, and at the Max Delbruck Center of Molecular Medicine in Berlin. He holds M.Sc. and Ph.D. degrees in biochemistry, an M.D. degree from Hannover Medical School in Hannover, Germany, and is an associate professor of Clinical Pharmacology at the University of Witten Herdecke in Witten, Germany. He has published over 20 peer-reviewed articles listed in PubMed, and is an inventor of 13 patent families resulting in over 60 patents. Elmar has designed and conducted international clinical trials from Phases I through IV, including hematopoietic stem cell transplantation and studies in hematology, immunology, gastroenterology, oncology, bone regeneration and in cardiovascular diseases.

Valentin Fulga

Dr. Valentin Fulga is a serial entrepreneur and executive in the life science industry, with particular focus on cell therapy. In 1997, he co-founded one of the first cell therapy companies in the world, Proneuron Biotechnologies. Since then, he founded 3 companies. He is now Founder and President of Hemostemix, which develops adult stem cell therapies for cardiovascular and neurodegenerative disorders.

Valentin was granted the Technology Pioneer Award by the World Economic Forum and was a delegate to the Forum’s Annual Meetings in Davos where he moderated a session about tissue engineering. In 2005, Valentin was listed as one of the future 100 most influential people in Israel by the economic journal The Marker and was a runner-up in the “CEO of the Year Contest” for 2006. Valentin is the inventor of over 40 granted and pending patents and the author of fifteen scientific and medical articles.

Surinder Kher

Dr. Surinder Kher serves as CEO Asia at Ecron Acunova where he is responsible for the expansion initiatives of Ecron Acunova in the Asia and MENA region.

A physician by training Dr Kher practiced Clinical Medicine for about seven years before joining the pharmaceutical industry over 18 years ago. His experience within the pharmaceutical industry includes early drug development, study management, pharmaco-vigilance, quality assurance, regulatory affairs to overall strategic business planning covering various therapeutic areas including diabetes, oncology, neuro-sciences and infectious diseases.

Dr Kher worked at Eli Lilly India for about 8 years where he was a part of the clinical research team that initiated GCP studies in India. Dr. Kher's career portfolio includes such positions as Senior VP at Vanthys Pharmaceutical Development, COO at DiagnoSearch Life Sciences (iGate Clinical Research) and CEO of Jubilant Clinsys

Ina Sarel

Ina Sarel is Vice President of Research and Development at Hemostemix. Ina has broad experience in cell therapy in international biotechnology companies in Israel and U.S.A. Previously she was Director of Research and Development at Theravitae, Project Manager at Proneuron Biotechnologies and Senior Scientist at Lonza (Cambrex), USA where she developed a stem cell research product (Normal Human Neural Progenitor Cells and Media) currently commercialized by Lonza.

Ina received an M.Sc degree in Endocrinology from the Hebrew University in Jerusalem and a Ph.D. in Neuroendocrinology from Boston University, USA.


| Terms of Use | Privacy Policy | Sitemap